Galapagos tested drug GSK2586184 on 66 patients with
chronic psoriasis and observed a 75 percent improvement in
significantly more patients than in the placebo group.
GSK, which owns the drug's commercial rights, will decide whether to
proceed with clinical trials, Galapagos said in a statement.
Galapagos said it could receive a milestone payment of up to 34
million euros ($46.94 million) as well as double-digit royalties as
the program proceeds towards commercialization.
($1 = 0.7243 euros)
(Reporting by Robert-Jan Bartunek; editing by Christopher Cushing)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.